Business Services
Retail
Therapy

Caladrius Biosciences

$3.73
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.48%) Today
-$0.02 (-0.48%) Today

Why Robinhood?

You can buy or sell CLBS and other stocks, options, ETFs, and crypto commission-free!

About

Caladrius Biosciences, Inc. Common Stock, also called Caladrius Biosciences, is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Read More Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Employees
25
Headquarters
Basking Ridge, New Jersey
Founded
1980
Market Cap
36.96M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
107.73K
High Today
$3.75
Low Today
$3.73
Open Price
$3.75
Volume
1.63K
52 Week High
$11.65
52 Week Low
$3.05

Collections

Business Services
Retail
Therapy
Healthcare
Manufacturing
Health
2015 IPO
US

News

Simply Wall St21h

How Do Analysts See Caladrius Biosciences, Inc. (NASDAQ:CLBS) Performing In The Next Couple Of Years?

Caladrius Biosciences, Inc.’s (NASDAQ:CLBS) announced its latest earnings update in December 2018, which revealed that losses became smaller relative to the prior year’s level as a result of recent tailwinds Below is my commentary, albeit very simple and high-level, on how market analysts perceive Caladrius Biosciences’s earnings growth trajectory over the next few years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a ...

4
Seeking AlphaMar 14

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2018 Earnings Conference Call Transcript

Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q4 2018 Earnings Conference Call March 14, 2019 4:30 PM ET Company Participants John Menditto - VP IR & Corporate Communications David Mazzo - President & CEO Joseph Talamo - SVP & CFO Conference Call Participants Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. Following management's prepar...

0
Yahoo FinanceMar 14

Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results

Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, NJ / ACCESSWIRE / March 14, 2019 / Caladrius Biosciences, Inc. (CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announces financial results for the three and twelve months ended December 31, 2018. "20...

27

Earnings

-$0.96
-$0.71
-$0.47
-$0.22
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.44 per share
Actual
-$0.36 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.